Related by context. All words. (Click for frequent words.) 72 receiving INTRON 67 peginterferon alfa 67 IXEMPRA 66 PEGylated anti 65 Emtriva Viread 65 COPEGUS 64 MULTAQ 64 mcg kg REBETOL 64 ribavirin therapy 64 flutamide 64 tipranavir r 64 evaluating tivozanib 63 abacavir lamivudine 63 myelodysplastic myeloproliferative diseases 63 alfa 2a 63 #mg #mg #mg [003] 63 tenofovir emtricitabine 63 PREZISTA r 63 budesonide pMDI 63 ZOLINZA 63 #mg dose [002] 63 MAGE A3 ASCI 63 benazepril 62 ORENCIA ® 62 Pharmacokinetics PK 62 amprenavir 62 severe renal impairment 62 q8h 62 plus COPEGUS 62 APTIVUS r 62 DOXIL 62 treatment naive genotype 62 relapsed MM 62 FIRMAGON 62 Mg Uk 62 BENICAR HCT 61 interferon alfa 2b 61 hematological parameters 61 atazanavir 61 mg QD 61 dexamethasone Decadron 61 LEXIVA 61 danazol 61 BARACLUDE ® 61 recurrent glioblastoma multiforme 61 Peg IFN 61 mg RDEA# 61 q#h 61 hypomagnesemia 61 lopinavir ritonavir plus 61 dose cohort 61 administered subcutaneously 61 ritonavir boosted 61 seroconverted 61 8mg/kg 61 weekly subcutaneous injections 61 antidiabetic drug 61 NRTI backbone 61 neutropenia dehydration dyspnea 60 TDF FTC 60 ribavirin RBV 60 emtricitabine tenofovir 60 piperacillin tazobactam 60 mcg dose 60 intravenous bolus 60 mcg doses 60 FASLODEX 60 enfuvirtide 60 saline placebo 60 #mg QD [002] 60 Peginterferon alfa 2b 60 nevirapine Viramune 60 rilpivirine 60 #mg/day [001] 60 REYATAZ 60 protease inhibitor PI 60 dapagliflozin plus 60 3TC lamivudine Epivir 60 ® lenalidomide 60 posaconazole 60 mcg BID 60 oral antidiabetic medication 60 ritonavir boosted atazanavir 60 ALT flares 60 aspartate aminotransferase AST 60 ertapenem 59 lopinavir r arm 59 mg eq 59 non splenectomized 59 lipid elevations 59 antiandrogen 59 VELCADE melphalan 59 HIV uninfected 59 ARIXTRA 59 metastatic GIST 59 hyperphenylalaninemia HPA due 59 ISENTRESS 59 mg q#h 59 HBsAg 59 fosamprenavir 59 achieved ACR# 59 patients coinfected 59 oxycodone CR 59 CIMZIA TM certolizumab pegol 59 poor metabolizers 59 NATRECOR R 59 antiandrogens 59 indinavir 59 pegylated interferon alpha 59 mg TID 59 pegylated interferon alfa 2a 59 AZT zidovudine Retrovir 59 #.#g/day 59 REYATAZ r arm 59 rFSH 59 HES CEL 59 seroprotection 59 zidovudine lamivudine 59 LEXIVA r 59 biologic DMARD 59 NovoLog ® Mix 59 anthracycline taxane 59 del 5q MDS 58 ARCOXIA 58 forodesine 58 LPV r 58 highly emetogenic 58 GnRH antagonist 58 irbesartan 58 #.#mg/dL 58 gestational hypertension 58 treatment naïve genotype 58 RLAI 58 #mg BID [003] 58 recurrent metastatic 58 onset idiopathic hypogonadism 58 rizatriptan 58 mg ustekinumab 58 HIV coinfected 58 estramustine 58 dasatinib Sprycel ® 58 4mg/kg 58 receiving immunosuppressive therapy 58 valacyclovir 58 CIMZIA TM 58 Viread Emtriva 58 VIRAMUNE XR 58 HBeAg seroconversion 58 antibody titer 58 NOLVADEX 58 peg IFN 58 CrCl 58 plus medroxyprogesterone acetate 58 HBeAg positive patients 58 humanized interleukin 6 58 tibolone 58 insulin detemir 58 elevated ALT 58 HBeAg 58 dosing cohort 58 tolterodine ER 58 telaprevir dosed 58 PREZISTA ritonavir 58 GnRH agonist 58 peginterferon alfa 2b 58 Aptivus ® 58 HBeAg negative 58 Bezielle 58 mg BID 58 peg interferon 58 Contrave# 58 undetectable HBV DNA 58 mg kg dose 58 infliximab monotherapy 58 certolizumab 58 HBeAg + 58 AVODART 58 VIRAMUNE 57 beclomethasone dipropionate 57 moderate renal impairment 57 ® emtricitabine 57 #mg/day [002] 57 mycophenolate mofetil 57 lispro 57 plus dexamethasone 57 SGPT 57 Peginterferon 57 mg qd 57 μg dose 57 adriamycin 57 seroprotective 57 virologically suppressed 57 tipranavir ritonavir 57 mycophenolate mofetil MMF 57 PegIFN RBV 57 peginterferon alpha 2a 57 REYATAZ ® 57 #mg dose [003] 57 NPH insulin 57 mitoxantrone plus 57 Capecitabine 57 reduce serum phosphate 57 amoxicillin clavulanate 57 Platinol ® cisplatin 57 COMBIVIR 57 Doxil ® 57 ARIMIDEX 57 decompensated liver disease 57 antiretroviral naive 57 K ras mutations 57 pyrazinamide 57 HBV infections 57 clodronate 57 deep venous thromboses 57 μg kg 57 mcg kg 57 Pemetrexed 57 complete cytogenetic response 57 See CONTRAINDICATIONS 57 comparator arm 57 ABC/3TC 57 APRISO 57 seronegative 57 Myelosuppression 57 HBeAg negative patients 57 stage IIIB 56 histologically confirmed 56 genotypic resistance 56 ug dose 56 mcg albinterferon alfa 2b 56 evaluable subjects 56 CLINICAL STUDIES 56 plus prednisone prednisolone 56 peginterferon alfa 2a #KD 56 #mg/m# [002] 56 ascending doses 56 adefovir 56 CTAP# Capsules 56 #mg/m# [001] 56 #mg ATC 56 prednisone prednisolone 56 virologic failure 56 antiretroviral naïve 56 Forodesine HCl 56 hypophosphatemia 56 anti HBs 56 5 Fluorouracil 56 daily subcutaneous injections 56 oral prednisone 56 Folfox 56 Flu Cy 56 dosing cohorts 56 β blocker 56 Peginterferon Alfa 2a 56 J Am Coll 56 aminotransferase elevations greater 56 serum aminotransferase levels 56 tamoxifen Nolvadex ® 56 KRAS mutations occur 56 FUSILEV enhances 56 creatinine clearance 56 receiving prophylactic anticoagulation 56 golimumab CNTO 56 placebo dexamethasone 56 pegIFN 56 severe neutropenia 56 atazanavir ritonavir 56 response CCyR 56 aPTT 56 mg/m2 dose 56 gastrointestinal stromal tumors GIST 56 blood phenylalanine Phe 56 Kivexa 56 mesalamine granules 56 cells uL 55 coinfected patients 55 mg m² 55 coinfected 55 chlorambucil 55 non squamous NSCLC 55 SVR# 55 recurrent VTE 55 Laquinimod 55 anagrelide 55 detectable HCV RNA 55 ibandronate 55 corticosteroid dose 55 antiplatelet medications 55 Paraplatin ® 55 gemcitabine cisplatin 55 serum calcium levels 55 ABRAXANE therapy 55 nucleoside analog 55 minimally symptomatic 55 alanine aminotransferase 55 doxorubicin cyclophosphamide 55 peginterferon 55 precancerous cervical lesions 55 serum phosphate 55 mcg mL 55 Amgen Neulasta ® 55 virological response 55 biochemical relapse 55 vicriviroc 55 postmenopausal osteoporotic women 55 elevated transaminases 55 sustained virological response 55 HER2 expression 55 plus prednisone 55 subcutaneous enoxaparin 55 gemcitabine carboplatin 55 interferon alfa 2a 55 combination antiretroviral therapy 55 CC genotype 55 q#d 55 achieved CCyR 55 oxycodone IR 55 FOLFIRI 55 recurrent genital herpes 55 ALT elevations 55 Zidovudine Tablets 55 PegIFN 55 azilsartan medoxomil 55 nadroparin 55 mg orally 55 advanced adenoma 55 alteplase 55 rapid virologic response 55 OADs 55 chronic HBV 55 PEG IFN 55 e antigen HBeAg 55 serum testosterone 55 nonnucleoside reverse transcriptase inhibitors 55 R entecavir 55 tipranavir 55 palivizumab 55 nevirapine NVP 55 undetectable viral 55 virologic breakthrough 55 achieved sustained virologic 55 -#.# log# copies mL 55 mg d 55 tirofiban 54 genotype 1b 54 CCyR 54 baseline HbA1c 54 experienced virologic failure 54 hepatorenal syndrome 54 adjunctive ABILIFY 54 Natalizumab 54 Pegasys plus Copegus 54 glycated hemoglobin levels 54 ACR# responses 54 HBeAg positive 54 huN# DM1 54 lopinavir r 54 lamivudine refractory patients 54 mg tid 54 virologic responses 54 bone marrow reticulin deposition 54 NMIBC 54 Telintra 54 thromboembolic events 54 definite stent thrombosis 54 octreotide LAR 54 Elitek 54 dalteparin 54 umol L 54 adefovir treated 54 ASCUS 54 antithymocyte globulin 54 FOLFOX4 54 HCV genotype 54 3mg/kg 54 mIU mL 54 baseline neutrophil counts 54 cART 54 HCV genotype 1 54 peginterferon alfa 2a 54 subcutaneous dose 54 TMC# [002] 54 serum urate 54 PEG Interferon alfa 54 investigational oral inhibitor 54 naïve HCV 54 morphometric vertebral fractures 54 KRAS mutant tumors 54 AZT 3TC 54 alemtuzumab treated 54 aminotransferases 54 chronic HCV infection 54 LHRH agonists 54 TAXOTERE R 54 serum concentrations 54 mg p = 54 plus methotrexate 54 Epoetin Alfa 54 #mg QD [001] 54 ALT normalization 54 CMV infection 54 KRAS mutations 54 abnormal cytology 54 pegfilgrastim 54 NNRTI resistance 54 BCG vaccinated 54 Q2W 54 Cutaneous T 54 beta blocker therapy 54 #mg BID [001] 54 virologic suppression 54 fasting plasma glucose FPG 54 administering XIFAXAN 54 cEVR 54 castrate resistant prostate cancer 54 fallopian tube carcinoma 53 sustained virologic response 53 trabedersen 53 palifermin 53 oral FTY# 53 reactogenicity 53 Pegylated Interferon 53 mg/m2/day 53 PREZISTA rtv 53 FluCAM 53 cervical intraepithelial neoplasia 53 glulisine 53 HALAVEN 53 Taxotere R 53 dacarbazine 53 concomitant antibiotics 53 binary restenosis 53 hematologic toxicity 53 thyrotropin levels 53 ceftriaxone 53 Arch Intern Med 53 seroconversion 53 IV tPA 53 Zoledronic acid 53 generalized edema 53 intramuscularly 53 hypogonadal 53 Valcyte 53 aged ≥ 53 acute GvHD 53 refractory NSCLC 53 -#.# log# 53 Relapsed Refractory 53 hepatitis C genotype 53 lopinavir ritonavir Kaletra 53 virological failure 53 chlamydial infection 53 androgen independent 53 PSA nadir 53 docetaxel Injection Concentrate 53 decitabine 53 daunorubicin 53 aminotransferase levels 53 Viral load 53 annualized relapse 53 stage IIIb IV 53 HBsAg positive 53 alanine aminotransferase ALT 53 HGPIN 53 lamivudine 53 #OHD levels 53 unresectable tumors 53 minimally symptomatic metastatic castrate 53 Thal Dex 53 HER2 negative 53 FOLFOX4 alone 53 serum potassium 53 #μg [002] 53 antibody titers 53 T2DM 53 HCV Genotype 53 undetectable viral load 52 PASI scores 52 neoadjuvant 52 splenectomized patients 52 extrapyramidal symptoms EPS 52 progesterone receptor negative 52 μg mL 52 transaminase levels 52 Taxotere ® 52 DAS# remission 52 pulmonary exacerbations 52 oral vancomycin 52 cyclophosphamide methotrexate 52 HIV HCV coinfected 52 nonpregnant women 52 imipenem 52 lopinavir 52 serum HCV RNA 52 neoadjuvant chemotherapy 52 sUA 52 transaminases 52 log# reduction 52 IFN alfa 52 adjunctive placebo 52 serum prostate 52 low dose Iluvien 52 Lenalidomide 52 5-FU/LV 52 Scale EDSS score 52 DOXIL ® 52 plus OBT 52 NSTE ACS 52 EGFR TKI 52 Decitabine 52 lymphoid blast 52 initiating HUMIRA 52 TNF antagonist 52 detemir 52 CsA 52 mg simvastatin 52 FOLFOX 52 autoantibody positive 52 recurrent NSCLC 52 clomiphene 52 remission CR 52 #mg/kg [002] 52 Adjuvant chemotherapy 52 argatroban 52 IELT 52 μg doses 52 ug kg 52 leukopenia 52 azathioprine 52 low dose cytarabine 52 mRCC 52 mucosal healing 52 hours postdose 52 anti EGFR antibody 52 epoetin alfa 52 aspartate aminotransferase 52 pCR 52 anemia hemoglobin 52 R abatacept 52 seropositive 52 lumbar spine BMD 52 chronic HCV genotype 52 #mg q8h 52 advanced hepatocellular carcinoma 51 DAPT 51 vaccine serotypes 51 milliliters mL 51 mg/m2 IV 51 cytidine nucleoside analog 51 mL/min/#.# m 2 51 #.#/#.# mmHg [001] 51 heavily pretreated 51 undetectable HCV RNA 51 Treatment Naive Patients 51 adjuvant endocrine therapy 51 relapsed ovarian cancer 51 debulking surgery 51 iPTH 51 bortezomib refractory 51 CRp 51 transferrin saturation 51 FOLFIRI alone 51 nonmetastatic 51 lamivudine monotherapy 51 dehydroepiandrosterone sulfate 51 â ‰ ¥ 51 relapsed SCLC 51 premenopausal 51 incidence ≥ 51 ng dL 51 Inhibin B 51 milligrams mg 51 Zometa hazard 51 ALT elevation 51 timepoint 51 Crohn Disease Activity 51 seropositive patients 51 adjuvant radiation 51 FOLPI 51 EBRT 51 dizziness nausea diarrhea 51 HCV infected 51 Twinrix 51 microg 51 coinfection 51 euthyroid 51 pmol L 51 CR nPR 51 underwent surgical resection 51 leukemia AML 51 tumors GIST 51 androgen deprivation 51 IU ml 51 vincristine doxorubicin 51 virologically 51 placebo PBO 51 azacitidine 51 nucleoside naive 51 metastatic renal cell carcinoma 51 thiazides 51 osteopenic 51 plus ribavirin 51 plasma uric acid 51 advanced adenomas 51 Cmax 51 baseline Hb 51 HIV RNA 51 plasma folate 50 autoantibody levels 50 baseline LDH 50 iniparib BSI 50 mIU ml 50 ug mL 50 castrate resistant 50 HBV DNA 50 prior chemotherapy regimens 50 μmol L 50 doxorubicin docetaxel 50 HbA 1c levels 50 CYP#D# genotype 50 mitoxantrone 50 lymphocytosis 50 CIN3 50 endometrial thickness 50 #mg/dl 50 plus MTX 50 TroVax ® 50 g dl 50 receiving APTIVUS r 50 triglyceride concentrations 50 adult chronic ITP 50 SLNB 50 cells/mm3 50 polyp recurrence 50 QTcF 50 peak plasma concentrations 50 aromatase inhibitor therapy 50 fasting triglyceride levels 50 CMV seropositive 50 mEq L 50 #ng/ml 50 achieved PASI 50 mU liter 50 mL/min/#.# m2 50 leucopenia 50 Cladribine tablets 50 underwent resection 50 spontaneous preterm birth 50 log# copies mL 50 telaprevir pegylated interferon 50 evaluable 50 NNRTIs 50 albumin excretion rate 50 serum uric acid 50 Index CDAI score 50 resistant hormone refractory 50 neutropenic 50 systemic immunosuppressive 50 mg dosed twice 50 creatinine ratio 50 serum testosterone levels 50 parous women 50 REYATAZ r 50 % Confidence Interval 50 mutated K ras 50 urine albumin 50 lactate dehydrogenase LDH 50 adenoma recurrence 50 CD4 + cell 50 Index CDAI 50 protein excretion 50 bioavailable testosterone 50 ErbB2 positive 50 imatinib therapy 50 #.#ng/ml 50 histologic subtype 50 virus HBV 50 anthracycline therapy 49 specific antigen PSA 49 BCIRG 49 serum creatinine levels 49 intravaginal ejaculatory latency 49 hormone receptor negative 49 intramuscular dose 49 lactate dehydrogenase 49 log# IU mL 49 RNA copies mL 49 + PH# 49 perinatal transmission 49 p#HER# positive 49 gout flares 49 pmol liter 49 ipsilateral stroke 49 baseline A1C 49 anthracycline containing 49 nmol liter 49 neutropenic patients 49 paclitaxel carboplatin 49 cells mcL 49 mcg Albuferon 49 mmHg diastolic 49 #mmHg [001] 49 Psoriasis Area 49 serum phosphate levels 49 Lupuzor ™ 49 HBV DNA levels 49 serum IgE 49 Neutropenia 49 serum potassium levels 49 liver enzymes ALT 49 homocysteine concentrations 49 liver histology 49 urinary albumin excretion 49 MADRS score 49 underwent liver transplantation 49 Kaplan Meier analysis 49 % CI #.#-#.# [003] 49 BRCA2 mutation carriers 49 lymphocyte count 49 TPV r 49 cervical lesions 49 undetectable viral loads 49 cells μL 49 mcg 49 non splenectomised 49 gastric pH 49 viral titers 49 undergo prostate biopsy 48 #ug [001] 48 genital lesions 48 CMV disease 48 neurologic progression 48 Calcium intake 48 cGy 48 cisplatin chemotherapy 48 mg subcutaneous 48 VZV 48 plasma concentrations 48 receiving ISENTRESS 48 undetectable virus HCV 48 PSADT 48 fluticasone propionate FP 48 blastic phase 48 Durezol 48 serum HBV DNA 48 complete cytogenetic 48 serum albumin 48 Circumcised men 48 ovarian carcinoma 48 Pred Forte 48 cotrimoxazole 48 ACR# response 48 x ULN 48 serum folate 48 progression TTP 48 lowest tertile 48 Retreatment 48 preoperative chemotherapy 48 metastatic renal cell 48 intravesical chemotherapy 48 hemoglobin A1c HbA1c 48 hip BMD 48 FTC TDF 48 #mmHg [002] 48 colorectal carcinoma 48 virologic response 48 febrile neutropenia 48 receiving antiretroviral therapy 48 cytogenetic responses 48 normal ULN 48 mcg linaclotide 47 serum PSA 47 R darbepoetin alfa 47 mg/m2 47 CR CRu 47 gastrointestinal stromal tumors 47 placebo p = 47 serum urate levels 47 epithelial ovarian 47 RBC folate 47 ALND 47 median CD4 47 timepoints 47 mCi m 2 47 serum ALT 47 mg calcium 47 pT3 47 pg mL 47 jana.mlcochova @ thomson.com 47 T2 lesion volume 47 platelet reactivity 47 mg Lucentis 47 #mg/dL [001] 47 glomerular filtration rate 47 doublet chemotherapy 47 mIU L 47 pulmonary exacerbation 47 bilateral oophorectomy 47 hormone refractory 47 sUA levels 47 IU mL 47 CDAI 47 ng dl 47 concentration Cmax 47 Hb A1C 47 thyroid stimulating hormone 47 epithelial ovarian cancer 47 SHPT 47 neutrophil counts 47 kBq kg 47 viral suppression 47 neoadjuvant therapy 46 undergoing radical prostatectomy 46 Hgb 46 erythrocyte sedimentation rate 46 #Gy 46 orchiectomy 46 virological suppression 46 -#.# mg dL [002] 46 plasma HCV RNA 46 bFGF 46 HbA1C levels 46 paraprotein 46 X ULN 46 basal cell carcinoma BCC 46 A1c levels 46 hemoglobin Hb 46 unresectable Stage III 46 prehypertensive 46 Hazard Ratio 46 Kidney Int 46 μg d 46 % CI #.#-#.# [006] 46 μg ml 46 CD3 + 46 pg ml 46 hemoglobin concentrations 46 Kaplan Meier estimates 46 Ishak fibrosis score 46 titers 46 plasma leptin 46 μg L 46 micrograms mL 46 noncarriers 46 docetaxel 46 DAS# [002] 46 Acute myeloid leukemia 46 CD4 lymphocyte count 46 mmol l 46 treatment naļve 46 HbA1C 46 copies mL 46 highest tertile 46 neurodevelopmental impairment 46 haematological toxicity 46 leukocytosis 46 RBC transfusion 46 interquartile range 46 EGFR mutation positive 46 copies ml 45 EDSS score 45 ergocalciferol 45 hemoglobin concentration 45 CI #.#-#.# [001] 45 stage IIIB IV 45 serum phosphorus levels 45 viremia 45 URTI 45 leukocyte count 45 adjuvant cisplatin 45 adjuvant chemotherapy 45 XL# administered orally 45 undergone splenectomy 45 Stage IIB 45 Median PFS 45 prostate cancer mCRPC 45 prior nephrectomy 45 g dL 45 serum sodium 45 asymptomatic carotid stenosis 45 mm Hg systolic 45 ug ml 45 plasma viremia 45 methylmalonic acid 45 mU L 45 pancreatic adenocarcinoma 45 μg liter 45 CDAI score 45 nonfasting triglyceride levels 45 oral clodronate 44 HER2 positive tumors 44 SCr 44 median PFS 44 nmol l 44 cranial irradiation 44 operable breast cancer 44 mmHg systolic 44 mm ³ 44 IgM 44 #.#mmHg 44 achieve sustained virological 44 ml kg 44 mg dl 44 IFN α 44 postoperative mortality 44 neutrophil count 44 Viread Emtriva Sustiva 44 fragility fracture 44 PASI score 44 RBC transfusions 44 absolute neutrophil count 44 mg dL 44 systemic embolism 44 vitamin D2 44 mCRPC 44 p = #.# [003] 44 mcL 44 mg m 44 nanomolar 44 TRAIL induced apoptosis 44 biochemical recurrence 44 mmol liter 44 endometrial ovarian 44 log# 44 CK MB 43 seminoma 43 DX DEC# 43 Tysabri infusions 43 Free Survival PFS 43 inhibitory concentration 43 neuropathy sensory 43 α tocopherol 43 rapid virological response 43 lipase units 43 initiating HAART 43 refractory ischemia 43 % CI #.#-#.# [007] 43 plasma urate 43 baseline CD4 43 extracapsular extension 43 G CSF 43 mmol L 43 Hb levels 43 Rectal cancer 43 Median survival 43 Rapid Virological Response 43 P = .# 43 lymphocyte counts 42 HCV RNA 42 placebo p 42 prevalent vertebral fracture 42 Median progression 42 maintaining Hb 42 viral loads 42 distant metastases 42 HAART 42 isoniazid preventive therapy 42 Neutrophil 42 nmol L 41 microliter 41 plasma glucose 41 elevated hsCRP 41 bone metastasis 41 neutropenia 41 absolute lymphocyte 41 trastuzumab 41 platelet counts 40 nM 40 ng mL 40 CD4 cells 40 distant metastasis 40 micromoles 40 mmHg 40 p = .# [002] 40 nadir CD4 cell 40 ng ml 40 placental malaria 40 #.#mmol l [002] 39 CD4 + 39 mm3 39 achieved undetectable HCV 39 CDI recurrence 39 HAQ DI 38 CD4 counts 38 viral load 38 platelet count 38 CD4s 37 baseline CD4 + 37 osteoporotic 36 CD4 + cells 35 microlitre 35 CD4 cell 34 CD4 count 34 CD4 + T 32 telomeres shorten 31 cubic milliliter 31 cubic millimeter 30 CD4 T 25 CD4